LC
ASND icon

Lavaca Capital’s Ascendis Pharma A/S ASND Stock Holding History

Lavaca Capital’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,928
Closed -$248K – 151
2021
Q1 		$248K Buy
+1,928
New +$293K 0.02% 123

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Lavaca Capital's ASND Position: Q2 2021 in Review

Lavaca Capital sold out of Ascendis Pharma A/S (ASND) in Q2 2021, closing a stake of 1,928 shares — an estimated $248K sold.

Lavaca Capital first reported a position in ASND in Q1 2021 and held it in 1 quarter. The position peaked at $248K in Q1 2021. 171 funds tracked by Wall St. Rank hold ASND as of Q2 2021.

  • Lavaca Capital reported no remaining Ascendis Pharma A/S position as of Q2 2021 after selling out during the quarter.
  • Lavaca Capital sold 1,928 Ascendis Pharma A/S shares in Q2 2021, an estimated $248K.
  • Lavaca Capital first reported a position in Ascendis Pharma A/S in Q1 2021 and held it in 1 quarter.
  • Lavaca Capital's Ascendis Pharma A/S position peaked at $248K in Q1 2021.
  • 171 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2021.

Based on Lavaca Capital's 13F filing for Q2 2021, filed 13 Aug 2021.